The Biology of IL-15: Implications for Cancer Therapy and the Treatment of Autoimmune Disorders

Journal of Investigative Dermatology Symposium Proceedings

Volumn 16, Issue 1, 2013, Pages S28-S30

  Waldmann, Thomas A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HU MIK BETA 1 MONOCLONAL ANTIBODY; HU-MIK-BETA-1 MONOCLONAL ANTIBODY; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR; MONOCLONAL ANTIBODY; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; TOFACITINIB;

ALOPECIA AREATA; ANIMAL; AUTOIMMUNE DISEASE; HUMAN; IMMUNOLOGY; METABOLISM; NEOPLASM; REVIEW; SIGNAL TRANSDUCTION; T CELL LEUKEMIA;

ALOPECIA AREATA; ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; HUMANS; INTERLEUKIN-15; LEUKEMIA-LYMPHOMA, ADULT T-CELL; NEOPLASMS; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RECEPTORS, INTERLEUKIN-15; SIGNAL TRANSDUCTION;

MLCS; MLOWN;

EID: 84902577044     PISSN: 10870024     EISSN: 15291774     Source Type: Journal    
DOI: 10.1038/jidsymp.2013.8     Document Type: Review

References (9)

1. Chen, J., Petrus, M., Bamford, R., et al. Increased serum soluble IL-15Rα levels in T-cell large granular lymphocyte leukemia. Blood 119 (2012), 137–143.
2. Chen, J., Petrus, M., Bryant, B.R., et al. Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism. Blood 111 (2008), 5163–5172.
3. Dubois, S., Mariner, J., Waldmann, T.A., et al. IL-15R alpha recycles and presents IL-15 in trans to neighboring cells. Immunity 17 (2002), 537–547.
4. Ju, W., Zhang, M., Jiang, J.K., et al. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Blood 117 (2011), 1938–1946.
5. Sneller, M.C., Kopp, W.C., Kory, J., et al. IL-15 administered by continuous intravenous infusion to rhesus macaques induces massive expansion of the CD8+ T effector memory population in peripheral blood. Blood 118 (2011), 6845–6848.
6. Waldmann, T.A., The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6 (2006), 595–601.
7. Waldmann, T.A., Conlon, K.C., Stewart, D.M., et al. Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia. Blood 121 (2013), 476–484.
8. Waldmann, T.A., Lugli, E., Roederer, M., et al. Safety (toxicity), pharmacokinetics, immunogenicity and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood 117 (2011), 4787–4795.
9. Yokoyama, S., Perera, P.-Y., Waldmann, T.A., et al. Tofacitinib, a Janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease. J Clin Immunol 33 (2013), 586–594.